Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy

Digestive Diseases and Sciences

Volumn 50, Issue 3, 2005, Pages 443-448

  Manes, G ^a   Pieramico, O ^b   Perri, F ^c   Vaira, D ^d   Giardullo, N ^e   Romano, M ^f   Nardone, G ^f   Balzano, A ^g  

^a CARDARELLI HOSPITAL   (Italy)

^b F Tappeiner Hospital   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e S G MOSCATI HOSPITAL   (Italy)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g University Federico II ^*

Author keywords

Antibiotic; Culture; Eradication; Failure; Helicobacter pylori; Omeprazole; Triple therapy

Indexed keywords

CLARITHROMYCIN; OMEPRAZOLE; TINIDAZOLE;

ADOLESCENT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BREATH ANALYSIS; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DYSPEPSIA; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID; STOMACH BIOPSY; TASTE DISORDER; TREATMENT FAILURE;

ADULT; AGED; ANALYSIS OF VARIANCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GASTRIC ACID; GASTROSCOPY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; ITALY; LOGISTIC MODELS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; OMEPRAZOLE; PROBABILITY; PROSPECTIVE STUDIES; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STOMACH ULCER; TREATMENT OUTCOME;

EID: 17444393560     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-2455-6     Document Type: Article

References (34)

1. van der Hulst RW, Rauws EA, Koycu B, Keller JJ, Bruno MJ, Tijssen JG, Tytgat GN: Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology 113:1082-1086, 1997
2. Thiede C, Morgner A, Alpen B, Wundisch T, Herrmann J, Ritter M, Ehninger G, Stolte M, Bayerdorffer E, Neubauer A: What role does Helicobacter pylori eradication play in gastric MALT and gastric MALT lymphoma? Gastroenterology 113: S61-S64, 1997
3. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784-789, 2001
4. Penston JG, McColl KEL: Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 43:223-243, 1997
5. Gisbert JP, Gonzalez L, Calvet X, Garcia N, Lopez T, Roque M, Gabriel R, Pajares JM: Proton pump inhibitor, clarithromycin and either amoxicillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 14:1319-1328, 2000
6. Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, Alpert LC, Genta RM: Factors influencing the eradication of H. pylori with triple therapy. Gastroenterology 102:493-496, 1992
7. Cutler AF, Schubert TT: Patient factors affecting H. pylori eradication with triple therapy. Am J Gastroenterol 88: 505-509, 1993
8. Labenz J, Leverkus F, Borsch G: Omeprazole plus amoxycillin for cure of Helicobacter pylori infection: factors influencing the treatment success. Scand J Gastroenteol 29:1070-1075, 1994
9. Perri F, Clemente R, Festa V, Quitadamo M, Conoscitore P, Niro G, Ghoos Y, Rutgeerts P, Andriulli A: Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection. Ital J Gastroenterol Hepatol 30:146-150, 1998
10. Katicic M, Prskalo M, Ticak M: Is PPI-triple therapy of greater efficacy in peptic ulcer than in non-ulcer dyspeptic patients? Gut 47(Suppl 1):A104, 2000
11. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E: Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 129:1027-1030, 1998
12. Labenz J, Stolte M, Blum AL, Jorias I, Leverkus F, Sollbohmer M, Bertrams J, Borsch G: Intragastric acidity as a predictor of the success of the Helicobacter pylori eradications: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 37:39-43, 1995
13. Miehlke S, Mannes GA, Lehn N, Hele C, Stolte M, Bayerdorffer E: An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Aliment Pharmacol Ther 11:323-329, 1997
14. Lind T, Rydberg L, Kyleback A, Jonsson A, Andersson T, Hasselgren G, Holmberg J, Rohss K. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 14:861-867, 2000
15. Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, Ishikawa T, Katsube T, Ogawa K, Ohkawa S: Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther 16:1811-1817, 2002
16. Miwa H, Ohkura R, Murai T, Sato K, Nagahara A, Hirai S, Watanabe S, Sato N: Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. Aliment Pharmacol Ther 13:741-746, 1999
17. Misiewicz JI, Harris AW, Bardhan KD, Levi S, O'Morain C, Cooper BT, Kerr GD, Dixon MF, Langworthy H, Piper D: One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut 41:735-739, 1997
18. Spinzi GC, Bierti L, Bortoli A, Colombo E, Fertitta AM, Lanzi GL, Venturelli R, Minoli G: Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 12:433-438, 1998
19. Veldhuyzen van Zanten SJ, Lauritsen K, Delchier JC, Labenz J, De Argila CM, Lind T, Treichel HC, Stubberod A, Cockeram A, Hasselgren G, Gothe L, Wrangstadh M, Sinclair P: One-week triple therapy with esomeprazole provides effective eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 14:1605-1611, 2000
20. Vergara M, Vallve M, Gisbert JP, Calvet X: Meta-analysis: comparative efficacy of different proton pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 18:647-654, 2003
21. Klok RM, Postma MJ, van Hout BA, Brouwers JRBJ: Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Phrmacol Ther 17:1237-1245, 2003
22. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standards. NCCLS Publication M7-A3. Villanova, PA: NCCLS, 1997
23. 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Gut 40:459-462, 1997
24. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G, European Helicobacter Pylori Study Group (EHPSG): Current concepts in the management of Helicobacter pylori infection. The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16:167-180, 2002
25. Lind T, Megraud F, Unge P, Bayerdorffer E, O'morain C, Spiller R, Veldhuyzen Van Zanten S, Bardhan KD, Hellblom M, Wrangstadh M, Zeijlon L, Cederberg C: The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116:248-253, 1999
26. Perri F, Villani MR, Festa V, Quintadamo M, Andriulli A: Predictors of failure of Helicobacter pilori eradication with the standard "Maastricht triple therapy." Aliment Pharmacol Ther 15:1023-1029, 2001
27. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T: Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Alim Pharmacol Ther 15:1929-1937, 2001
28. Furuta T, Shirai N, Takashima M, Xiao F, Hanai H, Sugimura H, Ohashi K, Ishizaki T, Kaneko E: Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 69:158-168, 2001
29. Sapone A, Vaira D, Trepidi S, Perna F, Gatta L, Tampieri A, Ricci C, Cantelli-Forti G, Miglioli M, Biagi GL, Paolini M: The clinical role of cytochrome P450 genotypes in Helicobacter pylori management. Am J Gastroenterol 98:1010-1015, 2003
30. Kawabata H, Habu Y, Tomioka H, Kutsumi H, Kobayashi M, Oyasu K, Hayakumo T, Mizuno S, Kiyota K, Nakajima M, Kimoto K, Inokuchi H, Kawai K: Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther 1:259-264, 2003
31. Miwa H, Misawa H, Yamada T, Nagahara A, Ohtaka K, Sato N: Clarithromycin resistance, but not CYP2C-19 polymorphism, has a major impact on treatment regimen success in 7-day treatment regimen for cure of H. pylori infection. A multiple logistic regression analysis. Dig Dis Sci 46:2445-2450, 2001
32. Bayerdoerffer E, Miehlke S, Mannes GA, Sommer A, Hochter W, Weingart J, Heldwein W, Klann H, Simon T, Schmitt W: Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori in patients with duodenal ulcers. Gastroenterology 108:1412-1417, 1995
33. Rodrigues AD, Roberts EM, Mulford DJ, Yao Y, Ouellet D: Oxidative metabolism of clarithromycin in the presence of human liver microsome: major role for the cytochrome P4503A (CYP3A)subfamily. Drug Metab Dispos 25:623-630, 1997
34. Furuta T, Ohashi K, Kobayashi K, Iida I, Yoshida H, Shirai N, Takashima M, Kosuge K, Hanai H, Chiba K, Ishizaki T, Kaneko E: Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin Pharmacol Ther 66:265-274, 1999